SEC Form 424B4 filed by Jyong Biotech Ltd.
$MENS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
New Taipei City, Taiwan, March 27, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). Pioneering Plant-Based TherapeuticsDeveloped in Taiwan, MCS®-2 is the world's only oral botanical new drug to have completed a global Phase III clinical trial for benign prostatic hyperplasia (BPH). Jyo
- Comprehensive review of recent milestones highlights statistically significant efficacy in prostate cancer prevention, discovery of novel lipid-modulating properties, and the execution of high-value commercial partnerships in South Korea and Vietnam.New Taipei City, Taiwan, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today issued a strategic corporate update. This review encapsulates a pivotal period characterized by the successful completion of the Phase II clinical trial for its lead candidate, MCS
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (NASDAQ:MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II clinical trial of MCS-8 (PCP) conducted in Taiwan. The results underscore MCS-8's previously indicated multifaceted clinical and commercial potential beyond its clinical evidence in pros
3 - Jyong Biotech Ltd. (0001954488) (Issuer)
3 - Jyong Biotech Ltd. (0001954488) (Issuer)
3 - Jyong Biotech Ltd. (0001954488) (Issuer)
6-K - Jyong Biotech Ltd. (0001954488) (Filer)
6-K - Jyong Biotech Ltd. (0001954488) (Filer)
SP 15D2 - Jyong Biotech Ltd. (0001954488) (Filer)